Objective: To investigate the prognostic significance of prostatic involvement by bladder urothelial carcinoma using the new 2009 TNM staging system. Methods: From 1993 to 2008, 77 consecutive men who were clinically and/or pathologically diagnosed with bladder cancer underwent radical cystectomy. Patients were classified into several groups, according to the presence, extent and invading pathway of prostatic involvement by urothelial carcinoma, whether there was stromal or non-stromal involvement, and whether there was contiguous or non-contiguous involvement. Cause-specific survivals were calculated in each group and they were compared. Results: Prostatic involvement was observed in 23 (30%) patients: 10 had non-contiguous non-stromal involvement, 5 had non-contiguous stromal involvement and 8 had contiguous stromal involvement. Patients with stromal involvement (both contiguous and non-contiguous) showed significantly shorter cause-specific survival compared with those without prostatic stromal involvement (P ¼ 0.002). The survival of patients with contiguous prostatic stromal involvement was similar to that of patients with non-contiguous prostatic stromal involvement (P ¼ 0.79). Multivariate analysis showed that prostatic stromal involvement (both contiguous and non-contiguous) (hazard ratio, 8.4; P , 0.001), lymph node involvement (hazard ratio, 4.4; P ¼ 0.016) and perivesical fat involvement (hazard ratio, 3.8; P ¼ 0.029) were predictive of cause-specific survival. Conclusions: The depth of prostatic involvement has a significant impact on survival for patients with bladder urothelial carcinoma; however, whether its origin is contiguous or noncontiguous does not appear to be important.
INTRODUCTION
Urothelial carcinoma (UC) involves the prostate in various ways, such as mucosa of the prostatic urethra, the prostatic ducts/acini and the stroma. The 2002 TNM classification has defined that prostatic involvement in bladder cancer was T4 disease, and no particulars about the depth of involvement were addressed (1, 2) . However, with regard to the issue of depth, the prognostic significance of prostatic stromal involvement by UC has recently been emphasized (3 -9) . In addition, several studies reporting on the invasion pathways of prostatic UC have shown that contiguous invasion, which indicates that bladder UC directly extends into the prostate through the bladder wall, and non-contiguous invasion are distinct clinicopathological features, and they should be separately staged (6 -8) . The new 2009 TNM classification of bladder cancer defines T4 as only prostatic stromal involvement directly from bladder cancer (10, 11) . This new definition of T4 disease is distinctly different from the old classification in terms of the depth and origin of prostatic involvement by UC. Therefore, it is important to assess the appropriateness of the new staging system. and/or prostate/prostatic urethra. The patients had been diagnosed with muscle-invasive UC or non-muscle-invasive UC unresponsive to intravesical therapy. Bilateral pelvic lymph node dissection extending from the common iliac bifurcation to the obturator area was performed in all patients. Urethrectomy was routinely performed, unless the urinary diversion was ileal neobladder. Pathological examinations were assessed with whole-mount step-sectioning at 5 mm intervals. The tumors were clinically and pathologically staged according to the International Union Against Cancer TNM classification of malignant tumors (seventh edition) (10) and the American Joint Committee on Cancer (AJCC) cancer staging manual (seventh edition) (11) . Pathologically, prostatic involvements by UC were divided into two groups: contiguous involvement defined as bladder UC extending into the prostate through the bladder wall and non-contiguous involvement defined as simultaneous presence of UC of the prostate and bladder, the latter not directly infiltrating into the prostate.
Actuarial survival was calculated using the Kaplan -Meier analysis, and univariate comparisons between groups were assessed by the log-rank test. Forward stepwise analysis with the Cox proportional hazard model was used to select a set of variables for predicting the prognostic outcomes. Differences and correlations with P , 0.05 were considered to be significant.
RESULTS
The median age of the patients was 68 years old (range, 31 -81 years) and the median follow-up period after cystectomy was 30 months (range, 0 -164 months). Twenty-three patients (29.9%) received cisplatin-based neoadjuvant chemotherapy and 22 patients (28.6%) received cisplatin-based adjuvant chemotherapy. Ileal conduit, cutaneous ureterostomy and ileal neobladder were performed in 54 (70.1%), 14 (18.2%) and 8 (10.4%) patients, respectively. One patient, who had received hemodialysis because of chronic glomerular nephritis, did not receive a urinary diversion operation. All of the patients were diagnosed with UC based on their pathology. Disease progression was observed in 31 patients (40.3%) and 20 patients (26.0%) died from UC progression.
According to the 2009 TNM staging system, T4 is defined as only prostatic stromal involvement directly from bladder cancer. The detailed depth and origin of prostatic involvement by UC are summarized in Table 1 . Of 77 patients, 54 patients (70.1%) had no prostatic UC and they were classified as pT0/a/is to pT3 according to the extent of the bladder wall UC. Twenty-three patients (29.9%) were positive for prostatic involvement by UC. Prostatic non-stromal involvement by UC was recognized in 10 patients (13.0%), and all of these UCs were non-contiguous prostatic involvement. Prostatic stromal involvement by UC was observed in 13 patients (16.9%). Of the 13 patients, 5 patients had noncontiguous prostatic stromal involvement and the remaining 8 patients had contiguous prostatic stromal involvement.
Among these patients with prostatic involvement by UC, only the patients with contiguous stromal involvement were classified into pT4 in the 2009 TNM staging system of bladder cancer. The other patients, who had no contiguous prostatic stromal involvement, were classified into pT0/a/is to pT3, according to the extent of the bladder wall UC. Patients with contiguous prostatic stromal involvement by UC (pT4 disease) had at least proper muscle involvement of the bladder wall UC. Details of the extent of bladder wall UC involvement are summarized in Table 1 .
Univariate analysis for cause-specific survival showed that patients with prostatic stromal involvement by UC had a statistically significant association with shorter survival compared with those with prostatic non-stromal involvement by UC (P ¼ 0.002) and those with no prostatic involvement (P , 0.001; Table 2 and Fig. 1 ). With regard to the origin of prostatic stromal involvement by UC, the survival rates were similar between patients with contiguous prostatic stromal UC and those with non-contiguous prostatic stromal UC (P ¼ 0.79; Table 2 and Fig. 2 ). Lymph node involvement and lymphovascular involvement also showed a statistically significant correlation with shorter survival (P , 0.001 for both) ( ; P ¼ 0.029) were entered the hazard model and could be proven independent poor-prognostic predictors (Table 3) .
DISCUSSION
The incidence of prostatic involvement by bladder UC is reported to range from 12 to 58% (5,12 -15) . In the current study, UC involvement of the prostate was recognized in 29.9% of the patients. These rates appear to be larger than those of primary prostatic UC, which are reported to range from 1 to 4% (12) . Prostatic involvement by bladder UC is relatively common compared with primary prostatic urethral UC; however, its staging interpretation is controversial. Various subcategories concerning the extent of prostatic involvement by UC have been reported, such as restricted prostatic mucosa and duct/acinus or invasion of the stroma and extra-prostatic area (3 -8) . The prognostic significance of prostatic stromal invasion by UC has been reported (3 -8) . Furthermore, the origin of prostatic UC is controversial. Some studies have reported prognostic differences between contiguous prostatic involvement and non-contiguous prostatic involvement (6 -8) . Although all prostatic involvement by bladder UC was defined as T4 in the 2002 TNM classification (1,2), the T4 criteria are confined to prostatic 'stromal' involvement directly from bladder cancer in the 2009 TNM classification (10, 11) . Five-year survival (overall, cancer-specific and recurrencefree) of prostatic stromal involvement by UC is reported to range from 21.5 to 36% (3,4,6 -8), 26% (3) and 18 -48%  (3,5,7 ). In the current study, 5-year cause-specific survival of patients with or without prostatic stromal involvement was 25.7 and 83.1%, respectively (P , 0.01). The survival rate of patients with prostatic non-stromal involvement was 89.5%, and this finding was similar to that of patients with bladder pT0/a/is (94.4%) and pT1 (81.0%) (data not shown). As previously mentioned, the depth of prostatic involvement by bladder UC, especially prostatic stromal invasion, has a distinct impact on patients' prognoses.
With regard to the invasion pathways of bladder UC to the prostate, i.e. the origin of prostatic UC, 5-year cause-specific survival rates of contiguous prostatic stromal UC and noncontiguous prostatic stromal UC were 23.3 and 20.0% (P ¼ 0.79), respectively, in the current study. Esrig et al. (7) reported that patients with contiguous prostatic (stromal) UC have a similar survival compared with those with noncontiguous prostatic stromal involvement concurrent with extra-vesical bladder UC, but they have a shorter survival compared with those with non-contiguous prostatic stromal involvement concurrent with organ-confined bladder UC. Pagano et al. (6) reported that patients with non-contiguous prostatic stromal involvement by UC have a better prognosis compared with those with contiguous (stromal) prostatic UC (P ¼ 0.022). On the other hand, some studies have reported a similar survival for both contiguous and non-contiguous prostatic stromal UC (3, 9) . Multivariate analysis in the current study showed that prostatic stromal involvement containing both contiguous and non-contiguous prostatic stromal involvement, lymph node involvement and perivesical fat involvement are independent predictors of a poor prognosis. On the other hand, contiguous prostatic stromal involvement was not independently proven as an indicator of poor prognosis. We consider that the strong correlation between contiguous prostatic involvement and prostatic stromal involvement affected these results. Patients with contiguous prostatic stromal UC may have a shorter survival than those with non-contiguous prostatic stromal UC, because all of the contiguous prostatic stromal UCs originated from muscle or perivesical fat invading bladder UC. However, in the current study, patients with both contiguous and non-contiguous stromal involvement showed a similar survival. This finding could be due to the small number in the current case series. Of the 77 patients, 23 (29.9%) and 22 (28.6%) patients received cisplatin-based chemotherapy, in the neoadjuvant and adjuvant settings, respectively. Patients who received the cisplatin-based chemotherapy in the neoadjuvant and/or adjuvant setting had no statistically significant difference on cause-specific survival, compared with those received no chemotherapy (P ¼ 0.68, data not shown) in the current study. These chemotherapies might affect the prognostic impacts. The authors, however, did not exclude patients receiving neoadjuvant and/or adjuvant chemotherapy, because these chemotherapies are carried out as ordinary treatments for bladder cancer and the current case series is not an enough number to accept the exclusion. The possibility that some limitations might affect the results of the current study cannot be denied. Figure 1 . Cause-specific survival according to the extent of the prostatic involvement, which includes both contiguous and non-contiguous involvements. Patients with prostatic stromal involvement had a statistically shorter survival compared with those with prostatic non-stromal involvement (P ¼ 0.002) and those without prostatic involvement (P , 0.001). UC, urothelial carcinoma. Figure 2 . Cause-specific survival according to the origin of the prostatic stromal involvement, which was composed of contiguous and non-contiguous involvements. The two groups show similar survival rates (P ¼ 0.79). In the current study, the authors investigated the prognostic impact of prostatic UC, according to the depth and origin of the prostatic UC involvement, and validated the new 2009 TNM staging system. We encourage revision of the new T4 criteria of bladder cancer; however, the issue of how non-contiguous prostatic stromal involvement by bladder UC should be dealt with still remains unclear. Non-contiguous prostatic stromal UC is often diagnosed as a part of bladder UC rather than as a primary urethral UC and is often a poor-prognostic factor. Therefore, we believe that case accumulation and further investigation are necessary for staging interpretation of non-contiguous prostatic stromal involvement by bladder UC in the TNM system of bladder cancer.
In the current study, we found that contiguous prostatic stromal involvement by bladder UC as well as noncontiguous prostatic stromal involvement by UC had a significant impact on survival. Further investigation is necessary for proper interpretation of non-contiguous prostatic stromal involvement by UC.
